Literature DB >> 32478749

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity.

Jingqi Pei1, Svetlana B Panina1, Natalia V Kirienko2.   

Abstract

The contribution of mitochondria to oncogenic transformation is a subject of wide interest and active study. As the field of cancer metabolism becomes more complex, the goal of targeting mitochondria using various compounds that inflict mitochondrial damage (so-called mitocans) is becoming quite popular. Unfortunately, many existing cytotoxicity assays, such as those based on tetrazolium salts or resazurin require functional mitochondrial enzymes for their performance. The damage inflicted by compounds that target mitochondria often compromises the accuracy of these assays. Here, we describe a modified protocol based on differential staining with two fluorescent dyes, one of which is cell-permeant (Hoechst 33342) and the other of which is not (propidium iodide). The difference in staining allows living and dead cells to be discriminated. The assay is amenable to automated microscopy and image analysis, which increases throughput and reduces bias. This also allows the assay to be used in high-throughput fashion using 96-well plates, making it a viable option for drug discovery efforts, particularly when the drugs in question have some level of mitotoxicity. Importantly, results obtained by Hoechst/PI staining assay show increased consistency, both with trypan blue exclusion results and between biological replicates when the assay is compared to other methods.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32478749      PMCID: PMC8310432          DOI: 10.3791/61295

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  37 in total

Review 1.  Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion.

Authors:  M Cecilia Caino; Dario C Altieri
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Trypan blue as an affordable marker for automated live-dead cell analysis in image cytometry.

Authors:  Susanne Melzer; Celio Siman Mafra Nunes; Denise Coutinho Endringer; Tadeu Uggere de Andrade; Attila Tarnok; Dominik Lenz
Journal:  Scanning       Date:  2016-06-29       Impact factor: 1.932

3.  Formation of solid tumors by a single multinucleated cancer cell.

Authors:  Zhang Weihua; Qingtang Lin; Asa J Ramoth; Dominic Fan; Isaiah J Fidler
Journal:  Cancer       Date:  2011-03-01       Impact factor: 6.860

Review 4.  Classification of mitocans, anti-cancer drugs acting on mitochondria.

Authors:  Jiri Neuzil; Lan-Feng Dong; Jakub Rohlena; Jaroslav Truksa; Stephen J Ralph
Journal:  Mitochondrion       Date:  2012-07-28       Impact factor: 4.160

Review 5.  Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors.

Authors:  T Hahn; M J Polanczyk; A Borodovsky; L V Ramanathapuram; E T Akporiaye; S J Ralph
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

Review 6.  The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.

Authors:  Stephen J Ralph; Sara Rodríguez-Enríquez; Jiri Neuzil; Emma Saavedra; Rafael Moreno-Sánchez
Journal:  Mol Aspects Med       Date:  2010-03-02

Review 7.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

8.  Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.

Authors:  Ryuji Yamaguchi; Edith Janssen; Guy Perkins; Mark Ellisman; Shinichi Kitada; John C Reed
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

9.  A mechanism for increased sensitivity of acute myeloid leukemia to mitotoxic drugs.

Authors:  Svetlana B Panina; Natalia Baran; Fabio H Brasil da Costa; Marina Konopleva; Natalia V Kirienko
Journal:  Cell Death Dis       Date:  2019-08-13       Impact factor: 8.469

10.  Utilizing Synergistic Potential of Mitochondria-Targeting Drugs for Leukemia Therapy.

Authors:  Svetlana B Panina; Jingqi Pei; Natalia Baran; Marina Konopleva; Natalia V Kirienko
Journal:  Front Oncol       Date:  2020-04-03       Impact factor: 6.244

View more
  1 in total

Review 1.  Mitocanic Di- and Triterpenoid Rhodamine B Conjugates.

Authors:  Sophie Hoenke; Immo Serbian; Hans-Peter Deigner; René Csuk
Journal:  Molecules       Date:  2020-11-20       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.